New treatment for skin lymphoma available on the NHS in England and Wales

NICE has recommended mogamulizumab for the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome

Logo for the National Institute for Health and Care Excellence

Earlier this year, we reported on the National Institute for Health and Care Excellence (NICE) decision not to recommend mogamulizumab for the treatment of people with skin lymphomas called mycosis fungoides or Sézary syndrome. We are delighted that, following a successful appeal against this decision, NICE has reconsidered its position. Mogamulizumab will now be available on the NHS in England and Wales to treat:

  • adults with Sézary syndrome who have had at least one previous course of whole body (systemic) treatment
  • adults with mycosis fungoides that is stage 2B or above, and who have had at least two previous courses of whole body treatment.

Lymphoma Action took part in the appeal process, together with our friends at Leukaemia Care, consultants representing the UK Cutaneous Lymphoma Group, and the company that developed mogamulizumab. We were fortunate to be joined by Stan, our patient representative, who shared his experience of mogamulizumab.

 
We’re really grateful and delighted with this decision. Mogamulizumab can have a life changing impact for those people affected by skin lymphoma who have limited treatment options and this is a great outcome for them. We were privileged to be part of the process alongside others, and to represent the patient voice with our patient advocate Stan.
Ropinder Gill, Chief Executive at Lymphoma Action

Mogamulizumab is already available for NHS use in Scotland. Northern Ireland usually follows NICE recommendations.

Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.

11 November 2021